Marina Noris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1269438/publications.pdf

Version: 2024-02-01

217 papers	19,868 citations	10389 72 h-index	11308 136 g-index
222 all docs	222 docs citations	222 times ranked	13887 citing authors

#	Article	IF	Citations
1	Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrology Dialysis Transplantation, 2023, 38, 283-290.	0.7	12
2	Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. Nephrology Dialysis Transplantation, 2022, 37, 239-254.	0.7	63
3	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Advances, 2022, 6, 866-881.	5.2	31
4	The state of complement in COVID-19. Nature Reviews Immunology, 2022, 22, 77-84.	22.7	159
5	Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy. Journal of Immunology, 2022, 208, 1772-1781.	0.8	2
6	Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice. Stem Cell Research and Therapy, 2021, 12, 332.	5.5	3
7	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. Frontiers in Immunology, 2021, 12, 711915.	4.8	2
8	CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Frontiers in Genetics, 2021, 12, 670727.	2.3	11
9	The case of complement inhibitors. Advances in Biological Regulation, 2021, 81, 100822.	2.3	4
10	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS ONE, 2021, 16, e0261113.	2.5	25
11	Autotaxin Inhibitor Protects from Chronic Allograft Injury in Rat Kidney Allotransplantation. Nephron, 2020, 144, 38-48.	1.8	6
12	Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?. Kidney International, 2020, 98, 1084-1087.	5.2	8
13	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood, 2020, 136, 2103-2117.	1.4	82
14	Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. Frontiers in Medicine, 2020, 7, 579418.	2.6	8
15	Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c+F4/80+ Macrophages through IL-1R8 Regulation. Journal of the American Society of Nephrology: JASN, 2020, 31, 517-531.	6.1	16
16	The case of complement activation in COVID-19 multiorgan impact. Kidney International, 2020, 98, 314-322.	5.2	268
17	Challenges in Understanding Acute Postinfectious Glomerulonephritis: Are Anti-Factor B Autoantibodies the Answer?. Journal of the American Society of Nephrology: JASN, 2020, 31, 670-672.	6.1	8
18	Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatric Nephrology, 2019, 34, 1311-1323.	1.7	33

#	Article	IF	Citations
19	Hemolytic Uremic Syndrome. , 2019, , 294-301.e2.		0
20	Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bitÂof both?. Kidney International, 2019, 96, 13-15.	5.2	11
21	More about Factor H Autoantibodies in Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 1590-1592.	27.0	8
22	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Frontiers in Genetics, 2019, 10, 681.	2.3	11
23	C3 glomerulopathy â€" understanding a rare complement-driven renal disease. Nature Reviews Nephrology, 2019, 15, 129-143.	9.6	223
24	Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. Frontiers in Immunology, 2019, 10, 853.	4.8	31
25	An ExÂVivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2019, 74, 56-72.	1.9	71
26	Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association. Nephron, 2019, 142, 264-270.	1.8	2
27	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. American Journal of Kidney Diseases, 2019, 74, 224-238.	1.9	45
28	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. Transplantation, 2019, 103, 1121-1130.	1.0	14
29	Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. Journal of Immunology, 2018, 200, 2464-2478.	0.8	130
30	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.6	136
31	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complexâ€"Mediated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 283-294.	6.1	89
32	Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2018, 29, 240-249.	6.1	34
33	Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. Frontiers in Immunology, 2018, 9, 2329.	4.8	37
34	ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A Â«KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMESÂ» (KDIGO) CONTROVERSIES CONFERENCE. Nephrology (Saint-Petersburg), 2018, 22, 18-39.	0.4	0
35	Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response. American Journal of Transplantation, 2017, 17, 2312-2325.	4.7	32
36	Insights into the effects of complement factor H on the assembly and decay of the alternative pathway C3 proconvertase and C3 convertase.. Journal of Biological Chemistry, 2017, 292, 6094.	3.4	0

#	Article	IF	Citations
37	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1237-1247.	4.5	146
38	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. Nature Communications, 2017, 8, 983.	12.8	124
39	Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. Seminars in Nephrology, 2017, 37, 447-463.	1.6	20
40	Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. Scientific Reports, 2017, 7, 11518.	3.3	89
41	Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?. American Journal of Kidney Diseases, 2017, 70, 754-757.	1.9	12
42	Interaction between multimeric VWF and complement: A fresh look to the pathophysiology of microvascular thrombosis. Molecular Immunology, 2017, 89, 133.	2.2	0
43	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. Journal of Immunology, 2017, 199, 1021-1040.	0.8	56
44	Thrombotic microangiopathy without renal involvement: two novel mutations in complementâ€regulator genes. Journal of Thrombosis and Haemostasis, 2016, 14, 340-345.	3.8	6
45	Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2016, 14, 2356-2367.	3.8	10
46	Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. Journal of the American Society of Nephrology: JASN, 2016, 27, 1305-1311.	6.1	29
47	Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. Journal of Biological Chemistry, 2016, 291, 8214-8230a.	3.4	12
48	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Molecular Immunology, 2016, 71, 131-142.	2.2	126
49	Liver transplantation for aHUS: still needed in the eculizumab era?. Pediatric Nephrology, 2016, 31, 759-768.	1.7	22
50	Association ofCFHR1homozygous deletion with acute myelogenous leukemia in the European population. Leukemia and Lymphoma, 2016, 57, 1234-1237.	1.3	5
51	Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood, 2015, 125, 2359-2369.	1.4	112
52	Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015. American Journal of Kidney Diseases, 2015, 66, 359-375.	1.9	132
53	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1011-1019.	4.5	47
54	Podocyte dysfunction in atypical haemolytic uraemic syndrome. Nature Reviews Nephrology, 2015, 11, 245-252.	9.6	49

#	Article	IF	Citations
55	Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. Annals of Oncology, 2015, 26, 1363-1371.	1.2	37
56	The role of complement in C3 glomerulopathy. Molecular Immunology, 2015, 67, 21-30.	2.2	78
57	Atypical aHUS: State of the art. Molecular Immunology, 2015, 67, 31-42.	2.2	236
58	Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. American Journal of Kidney Diseases, 2015, 66, 1067-1070.	1.9	25
59	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2002-2012.	4.5	12
60	A Novel Atypical Hemolytic Uremic Syndromeâ€“Associated Hybrid CFHR1/CFH Gene Encoding a Fusion Protein That Antagonizes Factor Hâ€“Dependent Complement Regulation. Journal of the American Society of Nephrology: JASN, 2015, 26, 209-219.	6.1	89
61	Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatric Nephrology, 2015, 30, 167-172.	1.7	62
62	A Novel Antibody against Human Factor B that Blocks Formation of the C3bB Proconvertase and Inhibits Complement Activation in Disease Models. Journal of Immunology, 2014, 193, 5567-5575.	0.8	14
63	An Unanticipated Role for Survivin in Organ Transplant Damage. American Journal of Transplantation, 2014, 14, 1046-1060.	4.7	9
64	Complement Factor B Mutations in Atypical Hemolytic Uremic Syndromeâ€”Disease-Relevant or Benign?. Journal of the American Society of Nephrology: JASN, 2014, 25, 2053-2065.	6.1	107
65	Hemolytic uremic syndrome. Seminars in Immunopathology, 2014, 36, 399-420.	6.1	136
66	Cardiovascular complications in atypical haemolytic uraemic syndrome. Nature Reviews Nephrology, 2014, 10, 174-180.	9.6	63
67	Kidney Transplantation From a Donor With Acute Kidney Injury: An Unexpected Outcome. American Journal of Transplantation, 2014, 14, 977-978.	4.7	1
68	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	288
69	Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity. Age, 2013, 35, 993-1005.	3.0	40
70	Overview of Complement Activation and Regulation. Seminars in Nephrology, 2013, 33, 479-492.	1.6	610
71	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transplant International, 2013, 26, 867-878.	1.6	148
72	Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations. American Journal of Transplantation, 2013, 13, 2201-2206.	4.7	51

#	Article	IF	Citations
73	Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype. Journal of the American Society of Nephrology: JASN, 2013, 24, 475-486.	6.1	308
74	ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy. Diabetes, 2013, 62, 3599-3609.	0.6	25
75	Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Current Opinion in Nephrology and Hypertension, 2013, 22, 704-712.	2.0	58
76	Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrology Dialysis Transplantation, 2013, 28, 2246-2259.	0.7	59
77	In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development. Journal of Immunology, 2013, 191, 2818-2828.	0.8	75
78	Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney International, 2012, 81, 903-918.	5.2	36
79	Eculizumab in a Patient with Dense-Deposit Disease. New England Journal of Medicine, 2012, 366, 1161-1163.	27.0	140
80	Non-muscle myosins and the podocyte. CKJ: Clinical Kidney Journal, 2012, 5, 94-101.	2.9	16
81	Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice. Journal of Immunology, 2012, 189, 3661-3668.	0.8	35
82	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood, 2012, 120, 440-448.	1.4	107
83	Thrombotic microangiopathies. , 2012, , 278-282.		1
84	STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nature Reviews Nephrology, 2012, 8, 622-633.	9.6	333
85	Discordant phenotype in monozygotic twins with renal coloboma syndrome and a PAX2 mutation. Pediatric Nephrology, 2012, 27, 1989-1993.	1.7	19
86	Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation. American Journal of Transplantation, 2012, 12, 2373-2383.	4.7	151
87	Prolonged cold ischemia accelerates cellular and humoral chronic rejection in a rat model of kidney allotransplantation. Transplant International, 2012, 25, 347-356.	1.6	19
88	Posttransplant recurrence of atypical hemolytic uremic syndrome. Journal of Nephrology, 2012, 25, 911-917.	2.0	6
89	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 412-422.	4.5	273
90	Both Darbepoetin Alfa and Carbamylated Erythropoietin Prevent Kidney Graft Dysfunction Due to Ischemia/Reperfusion in Rats. Transplantation, 2011, 92, 271-279.	1.0	25

#	Article	IF	Citations
91	Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation. Transplant International, 2011, 24, 829-838.	1.6	21
92	Erythropoietin enhances immunostimulatory properties of immature dendritic cells. Clinical and Experimental Immunology, 2011, 165, 202-210.	2.6	25
93	Thrombotic Microangiopathies: From Animal Models to Human Disease and Cure. Contributions To Nephrology, 2011, 169, 337-350.	1.1	13
94	MYO1EMutations and Childhood Familial Focal Segmental Glomerulosclerosis. New England Journal of Medicine, 2011, 365, 295-306.	27.0	221
95	Embryonic Stem Cells, Derived Either after In Vitro Fertilization or Nuclear Transfer, Prolong Survival of Semiallogeneic Heart Transplants. Journal of Immunology, 2011, 186, 4164-4174.	0.8	9
96	Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis. Journal of Immunology, 2011, 187, 172-180.	0.8	220
97	Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype. Blood, 2011, 118, 2219-2219.	1.4	0
98	Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. Current Opinion in Organ Transplantation, 2010, 15, 731-737.	1.6	23
99	Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1844-1859.	4.5	818
100	Thrombotic Microangiopathy After Kidney Transplantation. American Journal of Transplantation, 2010, 10, 1517-1523.	4.7	188
101	Atypical Hemolytic Uremic Syndrome Associated with Mutations in Complement Regulator Genes. Seminars in Thrombosis and Hemostasis, 2010, 36, 641-652.	2.7	41
102	Toward a B-cell signature of tolerance?. Kidney International, 2010, 78, 435-437.	5.2	5
103	Klotho in acute kidney injury: biomarker, therapy, or a bit of both?. Kidney International, 2010, 78, 1208-1210.	5.2	16
104	Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Seminars in Nephrology, 2010, 30, 395-408.	1.6	32
105	Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. , 2010, , 349-364.		0
106	The Toll-IL-1R Member Tir8/SIGIRR Negatively Regulates Adaptive Immunity against Kidney Grafts. Journal of Immunology, 2009, 183, 4249-4260.	0.8	46
107	Liver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2009, 20, 940-949.	6.1	154
108	Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. Kidney International, 2009, 75, 1050-1059.	5.2	28

#	Article	IF	Citations
109	Thrombomodulin Mutations in Atypical Hemolyticâ€“Uremic Syndrome. New England Journal of Medicine, 2009, 361, 345-357.	27.0	495
110	What not to learn from a meta-analysis. Nature Reviews Nephrology, 2009, 5, 186-188.	9.6	15
111	Proteasomal Processing of Albumin by Renal Dendritic Cells Generates Antigenic Peptides. Journal of the American Society of Nephrology: JASN, 2009, 20, 123-130.	6.1	88
112	Atypical Hemolyticâ€“Uremic Syndrome. New England Journal of Medicine, 2009, 361, 1676-1687.	27.0	1,140
113	Inherited thrombotic thrombocytopenic purpura. Haematologica, 2009, 94, 166-170.	3.5	29
114	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. Transplantation, 2009, 88, 614-619.	1.0	64
115	Complement and the atypical hemolytic uremic syndrome in children. Pediatric Nephrology, 2008, 23, 1957-1972.	1.7	192
116	Translational Mini-Review Series on Complement Factor H: Therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clinical and Experimental Immunology, 2008, 151, 199-209.	2.6	30
117	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Molecular Immunology, 2008, 45, 95-105.	2.2	136
118	Is local complement activation involved in renal damage in patients with atypical haemolytic uraemic syndrome?. Molecular Immunology, 2008, 45, 4101-4102.	2.2	1
119	Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertensionThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.. Canadian Journal of Physiology and Pharmacology, 2008, 86, 505-510.	1.4	42
120	Complement-Mediated Dysfunction of Glomerular Filtration Barrier Accelerates Progressive Renal Injury. Journal of the American Society of Nephrology: JASN, 2008, 19, 1158-1167.	6.1	63
121	The Complement Factor H R1210C Mutation Is Associated With Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2008, 19, 639-646.	6.1	81
122	Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells. Journal of Immunology, 2008, 181, 3933-3946.	0.8	405
123	Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2538-2543.	7.1	125
124	Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation. Kidney International, 2008, 74, 1420-1428.	5.2	6
125	Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood, 2008, 111, 624-632.	1.4	131
126	Effect of Seliciclib (CYC202, R-Roscovitine) on Lymphocyte Alloreactivity and Acute Kidney Allograft Rejection in Rat. Transplantation, 2008, 85, 1476-1482.	1.0	5

#	Article	IF	Citations
127	Thrombotic Microangiopathies. , 2008, , 294-312.		2
128	Screening for Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 591-596.	4.5	60
129	Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. Kidney International, 2007, 71, 1132-1141.	5.2	3
130	Regulatory T Cells and T Cell Depletion. Journal of the American Society of Nephrology: JASN, 2007, 18, 1007-1018.	6.1	224
131	Hemolytic Uremic Syndrome: A Factor H Mutation (E1172Stop) Causes Defective Complement Control at the Surface of Endothelial Cells. Journal of the American Society of Nephrology: JASN, 2007, 18, 506-514.	6.1	59
132	Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury. Transplantation, 2007, 84, 956-964.	1.0	94
133	DnIKK2-Transfected Dendritic Cells Induce a Novel Population of Inducible Nitric Oxide Synthase???Expressing CD4+CD25??? Cells with Tolerogenic Properties. Transplantation, 2007, 83, 474-484.	1.0	21
134	Chapter 14 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Handbook of Systemic Autoimmune Diseases, 2007, , 257-282.	0.1	0
135	Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Molecular Immunology, 2007, 44, 111-122.	2.2	115
136	Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. Molecular Immunology, 2007, 44, 1704-1708.	2.2	41
137	Where next with atypical hemolytic uremic syndrome?. Molecular Immunology, 2007, 44, 3889-3900.	2.2	61
138	The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Human Mutation, 2007, 28, 222-234.	2.5	160
139	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2006, 96, 454-464.	3.4	72
140	Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood, 2006, 108, 1267-1279.	1.4	652
141	Thrombotic Thrombocytopenic Purpura-Then and Now. Seminars in Thrombosis and Hemostasis, 2006, 32, 081-089.	2.7	52
142	Complement Factor H Gene Abnormalities in Haemolytic Uraemic Syndrome: From Point Mutations to Hybrid Gene. PLoS Medicine, 2006, 3, e432.	8.4	6
143	Adeno-Associated Virusâ€“Mediated CTLA4Ig Gene Transfer Protects MHC-Mismatched Renal Allografts from Chronic Rejection. Journal of the American Society of Nephrology: JASN, 2006, 17, 1665-1672.	6.1	31
144	Immunophenotypic Analysis of Cellular Infiltrate of Renal Allograft Biopsies in Patients with Acute Rejection after Induction with Alemtuzumab (Campath-1H). Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 539-545.	4.5	27

#	Article	IF	Citations
145	Outcome of Renal Transplantation in Patients with Nonâ€“Shiga Toxinâ€“Associated Hemolytic Uremic Syndrome: Prognostic Significance of Genetic Background. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 88-99.	4.5	201
146	Non-Shiga toxin-associated hemolytic uremic syndrome. , 2006, , 65-83.		6
147	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2006, 96, 454-64.	3.4	20
148	Dendritic Cells Genetically Engineered with Adenoviral Vector Encoding dnIKK2 Induce the Formation of Potent CD4+ T-Regulatory Cells. Transplantation, 2005, 79, 1056-1061.	1.0	32
149	Effect of a Novel Immunosuppressant, ST1959, on the Immune System and Renal Allograft Survival in Rats. Transplantation, 2005, 80, 231-236.	1.0	2
150	Pretransplant Donor Peripheral Blood Mononuclear Cells Infusion Induces Transplantation Tolerance by Generating Regulatory T Cells. Transplantation, 2005, 79, 1034-1039.	1.0	27
151	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood, 2005, 106, 925-928.	1.4	57
152	Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney International, 2005, 67, 1753-1761.	5.2	126
153	Hemolytic Uremic Syndrome: A Fatal Outcome after Kidney and Liver Transplantation Performed to Correct Factor H Gene Mutation. American Journal of Transplantation, 2005, 5, 1146-1150.	4.7	116
154	Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?. Nature Clinical Practice Nephrology, 2005, 1, 2-3.	2.0	19
155	Complement Factor H Mutation in Familial Thrombotic Thrombocytopenic Purpura with ADAMTS13 Deficiency and Renal Involvement. Journal of the American Society of Nephrology: JASN, 2005, 16, 1177-1183.	6.1	129
156	Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thrombosis and Haemostasis, 2005, 93, 443-452.	3.4	81
157	Reduced Nitric Oxide Bioavailability In a Baboon Model of Shiga Toxin Mediated Hemolytic Uremic Syndrome (HUS). Renal Failure, 2005, 27, 635-641.	2.1	8
158	Binding of Complement Factor H to Endothelial Cells Is Mediated by the Carboxy-Terminal Glycosaminoglycan Binding Site. American Journal of Pathology, 2005, 167, 1173-1181.	3.8	108
159	Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2005, 16, 1035-1050.	6.1	478
160	Mechanisms of Disease: pre-eclampsia. Nature Clinical Practice Nephrology, 2005, 1, 98-114.	2.0	259
161	Nitric Oxide Synthetic Capacity in Relation to Dialysate Temperature. Blood Purification, 2004, 22, 203-209.	1.8	22
162	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney International, 2004, 66, 1959-1965.	5.2	52

#	Article	IF	Citations
163	Natural versus Adaptive Regulatory T Cells. , 2004, 146, 121-131.		21
164	<scp>l</scp> -Arginine Depletion in Preeclampsia Orients Nitric Oxide Synthase Toward Oxidant Species. Hypertension, 2004, 43, 614-622.	2.7	139
165	Donor hematopoietic cells: central versus peripheral tolerance. Current Opinion in Organ Transplantation, 2004, 9, 284-288.	1.6	0
166	Diverse Functional Implications of ADAMTS13 Gene Mutations in Patients with TTP and Congenital Deficiency.. Blood, 2004, 104, 513-513.	1.4	5
167	ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney International, 2003, 64, 2253-2261.	5.2	30
168	Familial haemolytic uraemic syndrome and an MCP mutation. Lancet, The, 2003, 362, 1542-1547.	13.7	303
169	Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Human Molecular Genetics, 2003, 12, 3385-3395.	2.9	291
170	Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. Journal of Clinical Investigation, 2003, 111, 1181-1190.	8.2	315
171	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood, 2002, 100, 778-785.	1.4	200
172	Factor H family proteins: on complement, microbes and human diseases. Biochemical Society Transactions, 2002, 30, 971-978.	3.4	244
173	Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet, The, 2002, 359, 1671-1672.	13.7	152
174	Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. American Journal of Kidney Diseases, 2002, 40, 783-793.	1.9	66
175	Propionyl-l-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney International, 2002, 61, 1064-1078.	5.2	61
176	ACE inhibitors and AT1 receptor antagonists: Is two better than one?. Kidney International, 2002, 61, 1545-1547.	5.2	12
177	Single strand conformation polymorphism (SSCP) as a quick and reliable method to genotype M235T polymorphism of angiotensinogen gene. Clinical Biochemistry, 2002, 35, 363-368.	1.9	14
178	Complement factor H and hemolytic uremic syndrome. International Immunopharmacology, 2001, 1, 461-468.	3.8	24
179	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney International, 2001, 60, 653-663.	5.2	49
180	Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney International, 2001, 60, 831-846.	5.2	399

#	Article	IF	Citations
181	Thymic Microchimerism Correlates with the Outcome of Tolerance-Inducing Protocols for Solid Organ Transplantation. Journal of the American Society of Nephrology: JASN, 2001, 12, 2815-2826.	6.1	25
182	The Molecular Basis of Familial Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2001, 12, 297-307.	6.1	263
183	Combined Treatment with Mycophenolate Mofetil and an Angiotensin II Receptor Antagonist Fully Protects from Chronic Rejection in a Rat Model of Renal Allograft. Journal of the American Society of Nephrology: JASN, 2001, 12, 1937-1946.	6.1	32
184	Thymic Dendritic Cells Express Inducible Nitric Oxide Synthase and Generate Nitric Oxide in Response to Self- and Alloantigens. Journal of Immunology, 2000, 164, 4649-4658.	0.8	63
185	17Î²-Estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. American Journal of Physiology - Renal Physiology, 2000, 279, F626-F635.	2.7	25
186	Nitric Oxide/L-Arginine in Uremia. Mineral and Electrolyte Metabolism, 1999, 25, 384-390.	1.1	20
187	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. Blood, 1999, 94, 610-620.	1.4	44
188	Uremic Bleeding: Closing the Circle After 30 Years of Controversies?. Blood, 1999, 94, 2569-2574.	1.4	194
189	Interleukin-6 and RANTES in Takayasu Arteritis. Circulation, 1999, 100, 55-60.	1.6	216
190	Peripheral donor leukocytes prolong survival of rat renal allografts. Kidney International, 1999, 56, 1101-1112.	5.2	33
191	IgA nephropathy: A stem cell disease?. Kidney International, 1999, 56, 1964-1966.	5.2	8
192	Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. American Journal of Kidney Diseases, 1999, 33, 746-753.	1.9	42
193	Peripheral donor leukocytes prolong survival of rat renal allografts. Kidney International, 1999, 56, 1101.	5.2	14
194	Physiology and Pathophysiology of Nitric Oxide in Chronic Renal Disease. Proceedings of the Association of American Physicians, 1999, 111, 602-610.	2.0	39
195	Hypocomplementemia Discloses Genetic Predisposition to Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Journal of the American Society of Nephrology: JASN, 1999, 10, 281-293.	6.1	139
196	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. Blood, 1999, 94, 610-620.	1.4	1
197	Are HUS and TTP genetically determined?. Kidney International, 1998, 53, 1085-1086.	5.2	7
198	Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: Implications for dialysis hypotension. American Journal of Kidney Diseases, 1998, 32, 115-124.	1.9	78

#	Article	IF	Citations
199	Identification of a Novel Geneâ€"SSK1â€"in Human Endothelial Cells Exposed to Shear Stress. Biochemical and Biophysical Research Communications, 1998, 246, 881-887.	2.1	6
200	Nitric oxide as a mediator of hemodynamic disturbances in acute renal failure associated with sepsis. , 1998, , 575-589.		0
201	Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney International, 1997, 52, 171-181.	5.2	138
202	SEQUENTIAL MONITORING OF URINE-SOLUBLE INTERLEUKIN 2 RECEPTOR AND INTERLEUKIN 6 PREDICTS ACUTE REJECTION OF HUMAN RENAL ALLOGRAFTS BEFORE CLINICAL OR LABORATORY SIGNS OF RENAL DYSFUNCTION. Transplantation, 1997, 63, 1508-1514.	1.0	53
203	A Putative Role of NO and Oxidant Injury in the Pathogenesis of Hemolytic Uremic Syndrome. , 1997, , 418-427.		0
204	Increased nitric oxide formation in recurrent thrombotic microangiopathies: A possible mediator of microvascular injury. American Journal of Kidney Diseases, 1996, 27, 790-796.	1.9	49
205	The role of vasoactive molecules of endothelial origin in the pathophysiology of normal pregnancy and pregnancy-induced hypertension. Current Opinion in Nephrology and Hypertension, 1996, 5, 347-352.	2.0	8
206	Systemic and fetal-maternal nitric oxide synthesis in normal pregnancy and pre-eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 1996, 103, 879-886.	2.3	61
207	Î±1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. Lancet, The, 1995, 345, 224-225.	13.7	22
208	New insights into circulating cell-endothelium interactions and their significance for glomerular pathophysiology. American Journal of Kidney Diseases, 1995, 26, 541-548.	1.9	25
209	Nitric Oxide Synthesis by Cultured Endothelial Cells Is Modulated by Flow Conditions. Circulation Research, 1995, 76, 536-543.	4.5	442
210	Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides.. Journal of Experimental Medicine, 1994, 180, 1967-1972.	8.5	36
211	Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. Kidney International, 1993, 44, 445-450.	5.2	204
212	Defective glomerular [3H]lysoPAF metabolism in the autologous phase of rabbit nephrotoxic nephritis. Kidney International, 1993, 44, 747-754.	5.2	1
213	Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. Kidney International, 1993, 43, 426-429.	5.2	22
214	Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome. Lancet, The, 1992, 339, 835-836.	13.7	26
215	Renal Prostacyclin Biosynthesis Is Reduced in Children With Hemolytic-Uremic Syndrome in the Context of Systemic Platelet Activation. American Journal of Kidney Diseases, 1992, 20, 144-149.	1.9	26
216	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. Kidney International, 1992, 42, 981-990.	5.2	21

#	Article	IF	Citations
217	Increased urinary excretion of platelet activating factor in mice with lupus nephritis. Life Sciences, 1991, 48, 1429-1437.	4.3	17